NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (NASDAQ:OCUL) concerning possible violations of federal securities laws.

On May 5, 2017, Ocular Therapeutix disclosed that the U.S. Food and Drug Administration had found minor issues at its manufacturing plant. However, on July 6, 2017, an article published by Seeking Alpha claimed that Ocular Therapeutix’s management had been misleading investors about manufacturing issues. One of the claims made by the article is that more than 50% of lots manufactured by Ocular Therapeutix contain bad product. Following this news, the price of Ocular Therapeutix shares fell $0.68 per share or over 6% to close at $9.50 per share on July 6, 2017. To obtain additional information, go to:

http://www.zlkdocs.com/OCUL-Info-Request-Form-5929?wire=2

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170707005638/en/